Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service antireflux & hiatal hernia surgery cases in Louisiana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (180 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 7 | 474 | 42% |
| 2020 | 7 | 395 | 45% |
| 2021 | 7 | 471 |
Laparoscopic fundoplication and paraesophageal hernia repair. Professional codes (what the surgeon bills): CPT 43280, 43281, 43282; the hospital bills MS-DRG 326, 327, 328.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Louisiana; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 21 | 2,378−5.5%/yr | −5.5%/yr | 6.21.0× | 3% | 2,210 in 2030−1.2%/yr |
| Cholecystectomy & appendectomy |
Antireflux & hiatal hernia surgery in every state, and its device makers · Every procedure market in Louisiana · Every state · Compare with Texas
| 2024 |
| 371 |
| 60% |
| 2025 est. | ≈ 310 | – |
| 2026 est. | ≈ 300 | – |
| 51% |
| 2022 | 8 | 400 | 54% |
| 2023 | 7 | 413 | 58% |
| 2024 | 4 | 371 | 60% |
| 2025 from claims | – | 306 247–359 | 61% |
| 2026 forecast | – | 303 237–380 | 62% |
| 2027 forecast | – | 301 224–398 | 63% |
| 2028 forecast | – | 300 212–414 | 63% |
| 2029 forecast | – | 299 203–428 | 64% |
| 2030 forecast | – | 297 195–441 | 65% |
In 2025, 27% inpatient hospital, 73% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| −2.6%/yr |
| 0.8 |
| 0% |
| 2,220 in 2030+4.2%/yr |
| Georgia | 14 | 800−3.2%/yr | −3.2%/yr | 0.9 | 0% | 1,030 in 2030+4.3%/yr |
| Virginia | 10 | 705−0.8%/yr | −0.8%/yr | 0.7 | 0% | 920 in 2030+4.6%/yr |
| North Carolina | 13 | 605−3.6%/yr | −3.6%/yr | 0.6 | 0% | 850 in 2030+5.9%/yr |
| Tennessee | 11 | 544+0.6%/yr | +0.6%/yr | 0.8 | 0% | 670 in 2030+3.5%/yr |
| South Carolina | 8 | 517+0.1%/yr | +0.1%/yr | 0.8 | 0% | 620 in 2030+3%/yr |
| Kentucky | 6 | 403−5.9%/yr | −5.9%/yr | 0.9 | 0% | 430 in 2030+1%/yr |
| Maryland | 9 | 381−0.3%/yr | −0.3%/yr | 0.4 | 0% | 520 in 2030+5.3%/yr |
| Alabama | 4 | 373−3%/yr | −3%/yr | 0.8 | 0% | 430 in 2030+2.3%/yr |
| Oklahoma | 4 | 319−1.5%/yr | −1.5%/yr | 0.7 | 0% | 340 in 2030+0.8%/yr |
| Mississippi | 3 | 297−1.9%/yr | −1.9%/yr | 0.8 | 0% | 300 in 2030+0.1%/yr |
| Arkansas | 1 | 248−7.6%/yr | −7.6%/yr | 0.7 | 0% | 260 in 2030+0.6%/yr |
| West Virginia | 2 | 134−13%/yr | −13%/yr | 0.6 | 0% | 100 in 2030−5.2%/yr |
| 56 |
| 2,158−8.2%/yr |
| −8.2%/yr |
| 5.41.2× |
| 3% |
| 2,120 in 2030−0.3%/yr |
| Colorectal resection | 3 | 766−7.5%/yr | −7.5%/yr | 1.91.1× | 0% | 690 in 2030−1.6%/yr |
| Breast reconstruction | 7 | 352+3.9%/yr | +3.9%/yr | 0.91.8× | 0% | 790 in 2030+14%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Johnson & Johnson MedTech leads with 99% of company spending on these surgeons in 2025, +1 pts on 2024.
In 2025, 2 companies reported engagement with Louisiana’s surgeons worth $3,593 in consulting, speaking, meals and travel tied to these products, about $898 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.